Pfizer rebuffs Starboard criticism as it raises forecasts
Pfizer chief executive Albert Bourla hit back at Starboard Value in its third-quarter results call, criticising the activist investor for complaining about the company's direction without coming up with any alternative ideas.
Pfizer raises full-year guidance by $1.5 billion amid activist investor pressure
Pfizer ( PFE) raised its full-year guidance by $1.5 billion and posted strong third quarter earnings Tuesday. The company now expects between $61 billion and $64 billion in revenue for the year and raised its outlook for adjusted earnings to $2.75 to $2.95 per share.
Pfizer CEO defends turnaround strategy as activist pressures management
By Michael Erman and Bhanvi Satija (Reuters) -Pfizer CEO Albert Bourla, under pressure from activist hedge fund Starboard Value, made his case to Wall Street on Tuesday that the drugmaker's turnaround is succeeding after it reported a higher-than-expected profit due to strong sales of COVID-19 treatment Paxlovid.
Pfizer CEO Defends Record Against Activist Attack
Pfizer shares have performed abysmally in recent years, as the company has failed to win investor confidence ahead of a wave of patent expirations coming by the end of the decade.
Pfizer CEO: The activist investors are 'too late'
CEO Albert Bourla is breathing a little easier after strong third quarter earnings results Tuesday and after the company raised full-year guidance by $1.5 billion, bringing an end to a tense month in which activist investor Starboard Value pressured the company,
Pfizer CEO defends performance after Starboard activist criticism
Pfizer’s chief executive Albert Bourla fired back at activist investor Starboard Value on Tuesday as the drugmaker upped its 2024 revenue projections, arguing the company was already pushing ahead with a turnaround and that its plan would pay off.
Pfizer CEO Albert Bourla goes one-on-one with Jim Cramer
Pfizer Chairman and CEO Albert Bourla joins 'Mad Money' host Jim Cramer to talk quarterly results, what's in the pipeline, ...
Pfizer CEO, Under Fire, Will Do ‘Whatever It Takes’ to Grow
Pfizer Inc. Chief Executive Officer Albert Bourla said he’ll do “whatever it takes” to keep profits growing, including further cost cuts, as he seeks to fend off allegations of mismanagement from ...
Pfizer Results May Temper Efforts for Shakeup Demanded by Activist Investor
Pfizer beat third-quarter profit and sales forecasts and raised its guidance on strong sales of its COVID-19 treatment.
Pfizer CEO says he welcomes good ideas as Starboard ups pressure on company
Pfizer reported an earnings beat Tuesday morning and raised its full-year outlook, seeing strength in sales of its Covid ...
devdiscourse13h
Pfizer's Strategic Pivot: Navigating Challenges Amid Investor Pressure
Pfizer CEO Albert Bourla addresses Wall Street, defending the drugmaker's turnaround strategy amidst pressure from activist ...
BioSpace15h
Pfizer Exceeds Wall Street’s Q3 Expectations Amid Activist Investor Pressure
CEO Albert Bourla, who is under attack from activist investor Starboard Value, got a much-needed victory on Tuesday as Pfizer ...
Pfizer's Oncology Triumphs Keep Investors Hooked Amid Market Volatility
Despite today's fall in Pfizer's share price, it beat my and Wall Street analysts' expectations for Q3 by a large margin. See ...
protothema.gr21h
Albert Bourla: The rehabilitation of the Pfizer strongman in 74 pages
Albert Bourla linked Pfizer ‘s name with the containment effort of the COVID-19 pandemic and this is the piece of history that belongs to him definitively, objectively and beyond any objection or ...
Pfizer’s guidance bump will not heal deeper wounds
Strip out the Covid product gains and Pfizer’s predicament is unchanged. It is struggling to convince investors there is life ...